More What is Benlysta? Monoclonal antibodies are made to target and destroy only certain cells in the body. This may help to protect healthy cells from damage. Benlysta is used together with other lupus medicines to treat active systemic lupus erythematosus SLE. Benlysta helps decrease disease activity more than when the other medicines are used alone.
|Country:||Trinidad & Tobago|
|Published (Last):||16 October 2009|
|PDF File Size:||12.49 Mb|
|ePub File Size:||9.31 Mb|
|Price:||Free* [*Free Regsitration Required]|
This medicine is authorised for use in the European Union. Benlysta is given to patients whose disease is still highly active despite standard treatment. Benlysta contains the active substance belimumab. Expand section Collapse section How is Benlysta used? Benlysta can only be obtained with a prescription and treatment should only be started and supervised by a doctor who has experience in the diagnosis and treatment of SLE.
Benlysta is available as a powder mg and mg that is made up into a solution for infusion drip into a vein; it is also available as a pre-filled pen and pre-filled syringe mg for injection under the skin. When Benlysta is given as an infusion into a vein, the recommended dose is 10 mg per kilogram body weight given over one hour.
The first three doses are given at two-week intervals. After this, Benlysta is given once every four weeks. In adults, Benlysta can also be given as a mg injection under the skin, once a week.
Patients may inject Benlysta themselves once they have been properly trained, if the doctor considers this appropriate. The doctor may interrupt or stop treatment if the patient develops reactions linked to the infusion such as rash, itchiness and difficulty breathing or hypersensitivity allergic reactions which may be severe and life-threatening and can develop several hours after Benlysta is given.
Patients should therefore be observed for several hours after at least the first two infusions. All infusions with Benlysta, and the first injection under the skin, should be given in a place where these reactions can be managed immediately if they occur. For more information about using Benlysta, see the package leaflet or contact your doctor or pharmacist. How does Benlysta work? SLE can affect almost any organ in the body, and is thought to involve a type of white blood cell called B lymphocytes.
Usually, B lymphocytes produce antibodies which help to fight infections. The active substance in Benlysta, belimumab, is a monoclonal antibody, a protein that has been designed to attach to and block a protein called BLyS which helps B lymphocytes to live longer.
By blocking the action of BLyS, belimumab reduces the life span of B lymphocytes, thereby reducing the inflammation and organ damage that occur in SLE. What benefit of Benlysta have been shown in studies? Benlysta given by infusion was shown to be more effective than placebo a dummy treatment in reducing disease activity when used as an add-on treatment for SLE in two main studies involving 1, adult patients with active SLE.
Results from a main study involving 93 children aged 5 to 17 years with active SLE showed that Benlysta was distributed in the body in a similar way as in adults and could be expected to have similar benefits.
Another study involved adult patients with active SLE, who received add-on Benlysta as an injection under the skin once a week for a year. What are the risks associated with Benlysta? The most common side effects with Benlysta which may affect more than 1 in 10 people are bacterial infections, such as bronchitis infection in the lungs and infection of the urinary tract structures that produce or carry urine , diarrhoea and nausea feeling sick. Infections may be more likely in younger children.
For the full list of side effects and restrictions of Benlysta, see the package leaflet. Why is Benlysta authorised in the EU? The medicine may cause infusion and hypersensitivity reactions as well as infections, but is generally well tolerated.
The Agency also noted the lack of effective alternative treatments for patients who have already tried standard treatments. What measures are being taken to ensure the safe and effective use of Benlysta? The company that markets Benlysta will provide further information on the safety of the medicine from a study and from a register of patients being followed up long-term. Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Benlysta have also been included in the summary of product characteristics and the package leaflet.
As for all medicines, data on the use of Benlysta are continuously monitored. Side effects reported with Benlysta are carefully evaluated and any necessary action taken to protect patients. Other information about Benlysta.
Estimates of the prevalence of arthritis and other rheumatic conditions in the United States: Biologics in oral medicine: However, there are still unmet needs. Circulating antibody-secreting cells were enumerated using enzyme-linked immunospot assay. No serious adverse events AEs were seen. Belimumab Benlysta The authors concluded that recent studies suggested several new agents including tocilizumab, belimumab, daratumumab, plerixafor, and C1 esterase inhibitor as potentially novel and effective therapies to employ in AMR treatment. The decrease in biomarkers of B-cell activation observed at week 28 persisted unchanged until week 52, with RF decreasing further.
BENLYSTA PRESCRIBING INFORMATION PDF